Imagine caring for a loved one with Alzheimer's disease, facing constant questions, challenges and uncertainty. Now, imagine having a trusted companion, a friendly and knowledgeable assistant, to ...

Prolonged rapid eye movement sleep latency may be an early indicator of Alzheimer’s disease and related dementias, according ...

A 3D model accurately mimicking the blood-brain barrier (BBB) in a laboratory environment has been successfully developed by ...

A new platform for studying neuroinflammatory diseases, utilizing advanced 3D bioprinting technology has been developed.

Research has revealed clear evidence that changes in the orchestration of brain oxygenation dynamics and neuronal function in Alzheimer's disease contribute to the neurodegeneration. Researchers found ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

All applications must fall within Alzheimer’s Research UK’s remit which covers biomedical research in Alzheimer’s disease and other dementias. Alzheimer’s Research UK funds research into treatment, ...

Many people use the terms Alzheimer’s disease and dementia as if they mean the same thing, but they actually refer to ...

Alzinova AB (publ) (ticker: ALZ) announces that another milestone in the development of the company's vaccine candidate ALZ-101 for Alzheimer's disease has been reached. All study participants have no ...

Whether you're curious to explore a healthy brain or brains affected by Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, or Frontotemporal dementia, the choice is yours. Tailoring ...

LATE-NC diagnostic criteria improve differentiation from Alzheimer's, addressing challenges in memory-loss syndromes and guiding therapeutic interventions.

Vigil Neuroscience, Inc., a clinical-stage biotechnology company listed on the Nasdaq under the symbol VIGL, recently unveiled promising results from its Phase 1 clinical trial for the experimental ...